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Proposa I  for  a 
COUNCIL  REGULATION  <ECl 
ON  FEES  PAYABLE  TO  THE  EUROPEAN  MEDTC'INES 
EVALUATION  AGENCY 
(presented  by  the  Commission) Ex,planatory memorandum 
Pursuant to Council Regulation (EEC) No 2309/93 of 22 July 19931 laying down Community 
p(()Cedures for the authorisation and supervision of  medicinal products for human and veterinary 
use  and  establishing  a  European  Agency  for  the  Evaluation  of Medicinal  Products  ("the 
Agency"}, the Council establishes the structure and the amount of  fees paid by undertakings for 
obtaining and maintaining a Community marketing authorisation and for other services provided 
by the Agency. 
After a start-up period of several years, the Agency should be capable; as far as possible, of 
financing itself. Fees will then constitute the Agency's main source of revenue. Therefore, the 
amount of fees should be faxed in such a manner that the Agency's operational capacity is not 
weakened due to financial shortcomings. Fees will be payable to the Agency for the examination 
and the review of  any application for authorisations for medicinal products. 
Furthermore, the Agency's budget will have to be in balance  .. The expenditure will have to be 
met by the Agency's real income. 
In a general way, the fees to be levied by the Agency should neither lay an undue burden on the 
applicants nor endanger the achievement of the Agency's primary task of providing scientific 
advice of the  highest  possible  quality  in  relation  to  the  authorisation  and· supervision  of 
medicinal products. 
With regard to the amounts of the various fees to be laid down, account must be taken of the 
international character of the Agency and its obligation to work under the linguistic regime of 
the Community and hence in nine different languages. The corresponding additional expenditure 
is considerable and has not to be dealt with at national level. 
More generally, any direct comparison of the structure and  the amount of fees  between the 
Agency and national  authorities should bear in  mind, among others, those two aspects cited 
above, i.e. the Agency is set up· as a supranational body under ·the law of  the EC and it will have 
to be self-funding. 
The Agency's fee structure should be based on the principles of  cost-effectiveness, payment 
for services effectively rendered and financial independence and should enable the Agency 
to  live  up to the  high  sciimtific  and  organisational standards as  set out in  the  basic 
Regulation• 
Therefore, the standard fee for obtaining a Community marketing authorisation in the centralised 
procedure should be comparable to the benefit derived from a single procedure and authorisation 
throughout the Community. It should be more or less equivalent to but in  no case substantially 
higher than the total offees charged by the 12 Member States. 
1 OJ L 214,24.08.1993, p. 1 
2 On the basis of  the information made available, the fees levied by Member States' authorities for 
a marketing authorisation for a new medicinal product, as it would be subject to the centralised 
procedure of the Regulation,  currently total  nearly  220,000  ECU  for  human  medicines  and 
II  0,000 ECU for veterinary medicines. In view of the likely increase of national fees until the 
end of 1994, a Community standard fee for obtaining a marketing authorisation in the centralised 
p~ure  set at 200,000 ECU for human and I 00,000 ECU for veterinary medicines meets the 
above requirement. 
lbat would be even more so as the standard fee is defined as the initial a»mprrelheuuve full fee 
covering all specific applications for the different strengths, schedules of dosage, routes and 
fonns of administration which are made simultaneously for & given medicinal product at the 
time of the  initial  application.  As  regards  veterinary  medicinal  products,  applications  for 
different species and for the establishment of Maximum Residue Limits (hereinafter referred to 
as MRLs) would equally be covered. 
By contrast, most Member States charge, on a separate basis, for different specific applications 
regarding the same medicinal product, even if made simultaneously with the initial application, 
so that the actual sum of fees for a standard application is quite often substantially higher than 
the one laid down for the issuing of  a marketing authorisation. 
The  extra  work  generated  by the  applicant's  right  to  appeal  against  an  optmon  adversely 
affecting his rights would equally be comprised in  the standard fee as it cannot reasonably be 
detached from the initial application for a Community marketing authorisation. 
The comprehensive character of  the fee should facilitate the collection of  all necessary data 
at one time and, by that means, streamline the authorisation procedure and make it most 
eost-effectiveoess.  -
Correspondingly and to the same end, an extension·fee is laid down for·the additional work and 
expenditure of  subsequent specific applications regarding the same medicinal product whenever 
an applicant willingly chooses to do so. 
On the other hand, applications not sustained by a full dossier pursuant to Article 4 of  Directive 
65/65/EEC and  Article 5 of Directive 81/851/EEC  respectively require  less work.  An  initial 
reduced fee duly takes into account this circumstance. 
For the same reasons, an application for a  veterinary medicinal  product for  use in  non-food 
producing animals where no MRL has to be established attracts the reduced fee  . 
. Applying the same principle of  payment for service effectively rendered, variations to the terms 
of existing  authorisations  either  administrative  or  otherwise,  which  do  not  require  full_ 
aSsessment  of the  product's  quality,  safety  and  efficacy  are  charged  according  to  their 
complexity  and  the  real  workload  linked  to  them  and  therefore  far  less  than  a  standard 
application. 
3 Two types of variations have then to be distinguished. The  fee  for an administrative variation 
type I can reasonably be set at 5,000 ECU whereas the one charged for all other variations type 
II is respectively 40,000 ECUfor human and 20,000 ECU for veterinary m~icines. 
The  work  involved  in  the  mandatory  five  yearly  renewal  of a  Community  marketing 
authorisation justifies a corresponding fee at the level of  a fee for a variation. 
For the reasons stated above, fees for arbitrations under the decentralised procedure should also 
be fixed on the principle of  service effectively rendered by the Agency. The work involved can 
be assessed at more or less the same level as the one of  a complex variation type II. 
The arbitration  procedure arises  from  differences  between  Member states about  the mutual 
recognition of marketing authorisations and  is  hence  independent of the  applicant's  attitude. 
Therefore, the levying of  an arbitration fee by the Agency must be compensated by a reduction 
by one half of national fees of all Member States other than the first where an application has 
been successful1y lodged. 
As regards inspections made successively to a marketing authorisation at the request or in  the 
interest of  its holder, a fee set at 10,000 ECU on a flat-rate basis is justified. It corresponds to the 
above principles of  service effectively rendered and cost-effectiveness.  · 
The nature of  the assessment of  a veterinary medicinal product as well as the size of the market 
involved ate substantially different from  those of a medicinal  product for ·hu~an use and do 
therefore justify a general reduction of  the fee; furthermore, it should be possible to take account 
of  the particular situation linked to the marketing of  certain veterinary medicinal products on an 
individual basis and this aim eould be best achieved under the special provision of a clause for 
reductions and waivers. 
As regards the evaluation of  applications for MRLs, it is up to the applicant to decide whether to 
apply separately for the establishment of MRLs or to do so together with an application for a 
CommunitY marketing authorisation in  which case the fee  incurred  for the evaluation of the 
application for authorisation covers the one for the establishment of  MRLs. 
If  however the applicant deliberately chooses to apply separately for the establishment ofMRLs, 
the additional work and expenditure should be recouped by means of  an Isolated-MRL-fee. 
As- regards all other fees for the assessment of veterinary medicinal products, the reasons for 
levying them or to abstain from it remain .identical to those stated above. 
4 Under exceptional circumstances as for example in  the case of medicinal products designed to 
treat oniy a limited number of patients of a particular disease (so-called orphan drugs), small 
sized businesses or for esSential public health reasons. there should be provisions for waivers or 
reductions of  the fees stated above. However, such cases should be decided only on the merits of 
each individual case by the management board on a proposal from the Director after hearing the 
competent Committee. 
The sarne.procedure should apply to the settling of disagreements which may arise about the 
classification of  an application under one of  the above fee items. 
/ 
5 . PROPOSAL FOR A COUNCIL REGULATION ON FEES PAYABLE TO THE 
EUROPEAN MEDICINES EVALUATION AGENCY . 
THE COUNCIL OF THE EUROPEAN UNION 
Having regard to the Treaty establishing the European Community, 
Having  regard  to  Council  Regulation  (EEC)  No  2309/93  of 22  July  1993  laying  down 
Community procedures for the authorisation and supervision of medicinal products for human 
and veterinary use and establishing a European Agency for the Evaluation·ofMedicinal Products 
("the Ageney"). and in particular Article 58 thereof,  · 
Having regard to the proposal from the Commission2, 
Whereas Article 58 of the Regulation  requires the Council to establish the strUcture and  the 
amount of  fees referred to in Article 57(1);  · 
Whereas Article 57(1 )of  the Regulation establishes that the revenues of  the Agency shall consist 
of a  contribution  of the  Community,  and  the  fees  paid  by  undertakings  for  obtaining  and 
maintaining  a  Community  marketing  authorisation  and  for  other  services  provided  by  the 
. Agency; 
Whereas  Article  6(3)  and  28(3)  of the  Regulation  respectively  require  an  application  for 
authorisation for a medicinal product be accompanied by the fee payable to the Agency for the 
. .  .. examination of  the application; 
. Whereas  the  standard  fee  should  be  defined  as  the  comprehensive  full  fee  covering  all 
applications for the different strengths, schedules of dosage, routes and forms of administration 
which are made simultaneously for a given medicinal product in  the initial request in  order to 
facilitate the collection of all  necessary data at one time and,  by that means,  streamline the 
authorisation procedure and make it most. cost-effective; 
Whereas to the same end, an extension fee  should  be  laid  down  for subsequent applications 
regarding a medicinal product which has already been authorised in order to take account of  the 
additional work and expenditure where an applicant chooses to submit the applications gradually 
and s~uently;  ·  ·  ·  · 
6 Whereas it should be provided for a reduced fee for applications not required to be sustained by 
a  full  dossier  pursuant  to  Article  4  of Directive  65/65/EEC  and  Article  5  of Directive 
811851/EEC respectively ·and  for applications concerning a medicinal  product for use  in  non~ 
food producing animals;  · 
Whereas variations, either administrative or other, to  the terms of existing authorisations not 
requiring  full  assessment  of the  product's  quality,  safety  and  efficacy  should  be  charged 
according to their complexity and the real workload linked to them and therefore far less than a 
stan~  application; 
Whereas the work involved in the mandatory five yearly renewal of a Community marketing 
authorisation justifies a corresponding fee at the level of  a fee for a complex variation; 
Whereas fees for arbitrations under the decentralised procedure should be fixed on the principle 
of  service effectively rendered by the Agency; whereas that work can be assessed at more or less 
the  same  level  as  that . involved  in  a  variation  requiring  a  complex  evaluation;  whereas 
furthermore the arbitration procedure arises from differences between Member States about the 
mutual  recognition  of marketing authorisations  and  is  hence  independent  of the  applicant's 
attitude;  whereas,  therefore,  the.  levying  of an  arbitration  fee  by  the  Agency  should  be 
compensated by a reduction by one halfof  ~ational  fees of  all Member States other than the first 
one where an application has been successfully lodged; 
Whereas.on the same grounds of  service effectively rendered a fee should be levied on a flat-rate . 
basis for any inspection made· successively to a marketing authorisation at the request or in the 
interest of  its holder; . 
Whereas the nature of  the assessment of  a veterinary medicinal product as well as the size of  the 
'market involved are substantially different from those of  a medicinal product for human use and 
do therefore justify a general reduction of  the fee;  whereas it should furthermore be possible to 
take account of the particular situation linked to the marketing of certain veterinary medicinal 
products  on  an  individual  basis;  whereas  this  aim  can  be  best  achieved  under the  special 
provisions of  a clause for reductions and· waivers; 
Whereas as regards the evaluation ofapplications for MRLs it is up to the applicant to decide 
whether to  apply  separately  for  the  establishment of MRLs  or to do so  together  with  his 
application for a  Community marketing authorisation  in  which case the fee  incurred  for  the 
evaluation of the application for authorisation should cover the  one for  the establishment of 
MRLs;  whereas,  however,  the  applicant  deliberately  chooses  to  apply  separately  for  the 
establishment of  MRLs, the additional work .and expenditure should be recouped by means of  an 
ISolated-MRL-fee;  · 
Whereas,  as  regards all other fees  for the  assessment ol  veterinary  medicinal  products,  the 
reasons for levying them or to abstain from it remain identical to those stated above; 
7 Whereas  it  should  be  provided  for  waivers  or  reductions  of the  fees  stated  above  under 
exceptional circumstances as for example in  the case of medicinal products designed to treat 
ooly a  limited number of patients of a particular disease (so-called orphan drugs), small sized 
businesses or for essential public health reascins; whereas it should be decided upon those cases 
only on the merits of each individual case by the management board; whereas to that effect, a 
proposal from the Ditector-has to be made after hearing the competent Committee; 
HAS ADOPTED TinS REGULATION: 
Article I 
Scope 
(I) Fees for obtaining and maintaining a Community marketing authorisation shall be levied in 
accordance with this regulation. 
(2) They shall be laid down in ECU. 
Article 2 
Applications for medicinal products for human use under the centraliSed procedure 
(J) Full fee  200.000 
It is the comprehensive standard fee for an application for a Community marketing authorisation 
of a  given  medicinal  product  sustained  by a  full  dossier.  It covers  all  applications  for the 
different strengths, schedules of dosage,  routes and  forms  of administration  which  are made 
simultaneously for that medicinal product at the time of  the initial application. 
(2) Reduced fee  100.000 
It is the reduced fee for an application for a Community marketing authorisation of a  given 
medicinal  product not required  to be  sustained  by  a  full  dossier  as provided  for  under  the 
exception rules of point 8 (a) of the second paragraph of Article 4 of Directive 65/65/EEC. It 
covers all applications for  the different strengths,  schedules of dosage,  routes and  forms  of 
administration  which are made simultaneously for thaf medicinal  product at the time of the 
initial application. 
(J) Extension fee ·  40.000 
It is the fee for each supplement or extension of  an existing Community marketing authorisation 
of a given medicinal product to different strengths, schedules of dosage,  routes and forms of 
administration. It applies where an applicant chooses to submit the applications gradually and 
subsequently to lake account of  the additionalwork and expenditure hereby caused. 
8 (4) variation fee type I  5.000 
It is· the'  fee for an admini.strative or minor change to an existing marketing authorisation which 
would  be  proposed  by  the  marketing  authorisation  holder  and  would  neither  change  the 
specifications  for  the  active  ingredient(s),  the  release  specifications  or  end  of shelf-life-
specifications as already authorised  nor alter the summary of product ·  characteristics  or the 
labelling of  the medicinal product 
(5) YariatiQn fee type II  40000 
It  is  the  fee  for all  other changes  proposed  by the  marketing  authorisation  holder  to  the 
particulars  referred  to  in  article 4  of Directive  65/65/EEC of an  existing  authorisation  not 
requiring a new application. 
(6) Five yearly rene\.val fee  40.000 
It is the fee due for the obligatory five yearly renewal of  a Community marketing authorisation 
after a review of  the available new information about the product. 
(7) Inspection fee  10.000 
It is the flat-rate fee for any inspection within the European Communities made at the request or 
in the interest of the holder of  a marketing authorisation. For inspections outside the European 
Communities travel expenses will be charged extra on the basis of  the effective cost. 
Article 3 
Applications for medicinal products for human use under the decentralised procedure 
ArbitratiOn fee  40.000 
It is the flat rate fee for the work of the Agency involved in the arbitration of disagreements 
between Member States on'the mutual recognition of a national marketing authorisation in  the 
decentralised procedure. 
Member States fees for delivering a national marketing authorisation are reduced by one half 
except  for  the  first  Member State that  issued  a  marke~ing authorisation  for  that  medicinal 
product. 
Article 4 
Applications for medicinal products for veterinary use under the centralised procedure 
(I) FyJJ fee  100.000 
It is the comprehensive standard fee for an application for a Community marketing authorisation 
of  a given medicinal product for use in food  producing animals sustained by a  fuJI  dossier. It 
covers all applications for the different species, strengths, schedules of  dosage, routes and forms 
·of  administration and for the establishment of an MRL which are made simultaneously for that 
medicinal product at the time of  the initial application. 
9 
•. (2) Reduced fee  50.000 
It is the' reduced fee  for  ~n application  for  a Community marketing authorisation of a  given 
medicinal  product not required  to  be  sustained  by  a  full  dossier as  provid¢ for  under the 
exception rules of  point 10 (a) ofthe second paragraph of Article 5 of Directive 811851/EEC or 
for an application concerning a  medicinal product for  use  in  non-food  producing animals.  It 
covers all applications for the different species, strengths, schedules of  dosage, routes and forms 
of administration which are made simultaneously for that medicinal product at the time of the 
initial application.  ·  · 
(3) Isolated MRL fee  50.000 
·It is the fee for an isolated establishment of  an MRL for a new medicinal product. 
(4) Extension fee  20.000 
It is the fee for each supplement or extension of  an existing Community marketing authorisation 
of a  given medicinal  product to different species. strengths. schedules of dosage, routes and 
forms  of administration.  It  applies  where  an  applicant  chooses  to  submit  the  applications 
gradually and  subsequently  to· take account of the  additional  work  and  expenditure  hereby 
caused. 
CS) Yarjatjon fee t)(pe I  5.000 
It is the fee for an administrative or minor change to an existing marketing authorisation which 
would  be  proposed  by. the  marketing  authorisation  holder  and· would  neither  change  the 
specifications  for  the  active  ingredient(s),  the  release  specifications  or  end  of shelf-life-
specifications as  already  authorised  nor alter the  summary of product characteristics or the 
labelling of  the medicinal product 
(6) variation fee type II  20.000 
It is  the  fee'  for· all  other  changes  proposed  by  the  marketing  authorisation  holder  to  the 
particulars referred to  in  Article 5 of Directive  81/851/EEC of an  existing authorisation  not 
requiring a new application. 
·  (2) fjye yearly renewal fee  20.000 
It is the fee due for the obligatory five yearly renewal of  a Community marketing authorisation 
after a review of  the availa~le· new information about the product. 
(8) Inspection fee  10.000 
It is the flat-rate fee·for any inspection within the European Communities made at the request or 
in the interest of  the holder of a marketing authorisation. For inspections outside the European 
Communities travel expenses Will be charged extra on the basis of  the effective cost. 
10 Article 5 
Applications for medicinal products for veterinary use under the decentralised procedure 
Arbitration fee  20.000 
It is the flat rate fee for the work of the Agency involved in  the arbitration of disagreements 
between Member States on the mutual recognition of  a national marketing authorisation in the 
decentralised procedure. 
Member States fees for delivering a national marketing authorisation are reduced by one half 
· except for  the first  Member  State that issued  a  marketing  authorisation  for  that medicinal 
produd.  · 
Article 6 
Waivers, fee reductions and dispute settlement 
(1) Under exceptional circumstances as for example in the case of  medicinal products designed 
to treat only a limited number of  patients of  a particular disease (so-called orphan drugs), small 
sized businesses or for essential public health reasons, the management board may decide upon 
waivers and fee reductions on the merits of  each individual case on a proposal from the Director 
who will have consulted the·competent Committee. 
(2) The same procedure shall apply to any disagreement which may arise about the classification 
of  an application under one of  the above fee items. 
Article 7 
Due date and belated payment 
(1) Fees in respect of  which the due date is not specified in this Regulation or Regulation (EEC) 
No 2309/93 of  22 July 1993 shall be due on the date of receipt of  the application for the service 
for which the fee is incurred. ·  · 
(2) Where any fee payable under this Regulation remains unpaid at its due date the Director may 
decide  not  to  make  or to suspend  services  dependent  upon  the  advance  payment  of the 
corresponding fee.  .. 
Article 8 
Implementing rules 
(1) Without prejudice to other provisions of  this Regulation or Regulation (EEC) No 2309/93 of 
22 July 1993, implementing rules to. be adopted by the Agency's management board shall lay 
down the due date for  fees  to  be  paid  under Article  l, the  methods of their payment,  the 
consequences of  belated or omitted payment and contain  ~II other provisions needed to put the 
present regulation into effect 
11 .  :~ 
(2} The same rules shall detennine the conversion rates in  national currencies of the fees and 
costs to· be levied under t~is Regulation and laid down pursuant to Article 1(2} in ECU. 
Artjcle·9 
Conversion of  procedures 
Fonner concertation procedures converted on 1 January 1995 to centralised procedures pursuant  · 
to Article 2 of  Directive 93/41/EEC attract the arbitration fee as laid down in Articles 3 and 5. 
Article JO 
Entry into force and legal effect 
· (1} This Regulation shall enter into force on the day following its publication in  the Official 
Journal of  the European Communities. 
(2) It shall be binding in its entirety and directly applicable in all Member States. 
Done at Brussels, ....................  ~ .................  =  ................ . 
•• 
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EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS 
.  '  .  •·  ~ 
PROPOSAL FOR A COUNCIL REGULATION 
ON. THE FEES PAY  ABLE BY UNDERTAKINGS 
FINANCIAL STATEMENT 
.  '  '  ' 
.,.· .. 
ARTICLE BS-306:  Subsidy for tbe European Agency  for the Evaluation of Medicinal 
Products· 
13 
!  ·  .. authot:ized apptopirations  appropriations requested  variation% 
·1994.  . 1995 
commitments  payments  commitments  payments  commitments  payments 
I  2  3  4  5 = 3/f  6=4/2 
7.500.000  6.800.000  9.500.000*  9.500.000*  37,8%  52%; 
*APB95 
1. Title 
Proposal for a Council implementing regulation on the fees paid by undertakings for obtaining 
and maintaining a-Community marketing authorization and for other services provided by the 
Agency.  ·  ·  ·  · 
l.  Budget. headings 
.  .  .·  . 
3. Legal basis·~ 
...  ; 
· Articles 57and 58 of  Regulation (EEC) No 2309/93 of22 July 1993. 
4. Description oftbe action 
',:·  ,...  '  .  ,  .  '· .....  . 
. 4_•1. Gelieralobjectlve 
Completion of  the internal market in the pharmaceuticals sector (medicinal products for human 
and  veterinary  use); ··  improved  public  health . arid  consumer  protection  throughout  the 
COnlJ_nuriity>-·  .  .  .  . .  ..  . 
., 
4.l  Spedfie objectives 
. Council  Regulation  (EEC) No 2309/93,  adopted  on  22  July  1993,  lays  down  (centralized) 
Community· procedures for the authorization and supervision of  medicinal products for human 
and veterinary use and establishes a European Agency for the Evaluation of  Medicinal Products. 
Three Council Directives (93/39/EEC, 93/40/EEC and 93/41/EEC), adopted on  14 June 1993, 
complete the system for the future authorization of medicinal products under the decentralized 
procedure.  .  . 
1  Including a reserve fund of  700 000 ecus 
14 .  ' .  ~ . 
-.'  '1 
The abovementioned Regulation entered into force on the day following the decision taken by 
the Heads ofState and Government on 29 October 1993 establishing, inter alia, the headquarters 
of  the Agency in London. 
As ofnow, the Agency officially exists and is due to become operational from 1 January 1995. 
The future system will entail: 
a)  the  creation  of  a  centralized  Community  authorization  issued  by  the  Commission 
(compulsory in the case of biotechnology products and veterinary medicinal products used 
as performance enhancers, optional in the case of  other· innovatory medicinal products); 
b)  the creation of a new decentralized procedure, based on the principle of mutual recognition 
which  will  enable  a  marketing  authorization  from  one  Member  State  to  be  extended 
gradually to the others; in the event of  disputes between Member States, the Agency will be 
asked to arbitrate, and its decision will be made binding by the Commission; 
c)  the introduction of  consolidated Community procedures for the collection and assessment of 
information about adverse  reactions  to  medicinal  products  and  for  the  adoption  by the 
Community of  appropriate regulatory measures (pharmacovigilance  ); 
d)  the  delivery  by  the  Commission  of a  scientific  opinion  on  the  maximum  veterinary 
medicinal product residue levels that can· be permitted in foodstuffs of  animal origin without 
entailingtisks for the consumer.  · 
.. .  .  .  .. 
Under Articles 57 and 58 of  the basic Regulation, the system will be financed from the Agency's 
own revenues which shall consist of a contribution from  the Community and the fees paid by 
undertakings for obtaining and maintaining a Community marketing authorization and for other 
servicesprovided by the Agency.  · 
The purpose of this implementing Regulation is  to establish a  structural framework for 
.  faxing the levels of  the fees referred to above. 
4.3 Duration 
Selectively tm,"geted measures 
4.4 Sectors of  the population targeted by the_ action 
a)  Approximately 2 000 European pharmaceuticals firms applying for authorization 
b)  Approximately  3 000  national  officials  required  to  work  together  through  the  Agency 
interface  · 
c)  Signific3.nt proportion of  the European population (sick persons) 
15 ....  ~. -, 
5. Classification of  the expenditure  .  . 
NC~,DC 
6. Type of  expenditure 
Full direct subsidy in 1994, partial subsidy from 1995. 
a)  Initial contribution (100%) from the Community bud&et in 1994 
In order to  launch the Agency's  activities,  it will be necessary to make  provisio~ for  a 
relatively  high  level  of start-up  investment  which  will  have  to  be  funded  from  the 
Community budget, since the Agency will not yet be in a position to provide services to the 
undertakings.  · 
b)  Partial subsidy from 1995_ 
From 1995 the Agency will be required to examine applications for authorization submitted 
by·  phannaceuticals  companies  on  a  fee-paying  basis,  thus  generating  revenue  for  the 
Agency's budget. 
Thus, a contribution from the Community budget is required (albeit on a decreasing scale up to 
1998) in respect of  the following: 
- as a balancing subsidy for the Agency's operating budget throughout the period during which 
proceeds from fees do not constitute a stable source of revenue capable of coping with major 
investment and start-up costs, i.e., until 1998;  · 
- to cover the considerable amount of investment required for the telecommunications network 
to  be·  installed  for·  the  exchange  of  information  and  ·warnings  between 
Commission/  Agency/competent authorities in the Member States. 
7. Financial impact on the operating approp~tions 
7  .1. Method of  calculating the  'total cost. of  the action 
On the basis of  the study carried out by the DRT consultants, but!il~bject to a reassessment of  the 
foreseeable work load (reduced riumber of  dossiers); investment and operating costs for the next 
five years are as follows: ·  · 
16 Costs iQ thousands ECU  1995  1996  1997  1998  1999 
Investment  964  704  - - -
operating expenditure  3.456  4.154  4.623  4.761  4.904 
Rapporteurs+experts  5.979  12.393  15.510  22.420  24.307 
Administrative costs + staff  12.481  16.541  18.446  27.257  30.610 
Translation Center in Luxembourg  3.000  5.000  5.800  8.200  9.000 
Total "Agency"  25.880  38.792  44.379  62.638  68.821 
7  .l  Itemized breakdowu 
VENTILATION  BUDGET94  APB95  VARIATION EN% 
Investment  3.105  964  -69% 
operating expenditure  1.756  3.456  +97% 
Administrative and staff  2.639  12.481  +373% 
costs 
payments rappJexperts  ---- 5.979 
Translation Center  ---- 3.000 
TOTAL  7.500  25.880  +245% 
As far as the variation in  rates  is  concerned, it should  be.· noted that the  1994  financial  year 
relates to the  launching of the Agency, whereas the  1995  financial  year (the  year when  the 
Agency becomes operational) represeJ:~ts the Agency's first genuine operating budget. 
7:J Provisional schedule of  commitment appropriations 
Not  applicable, since this is a subsidy. 
7.4 Subsidy under Beading BS-306 "Agency for tbe Eval~ation of  Medicinal Products" 
Since this is an autonomous body endowed with legal personality and possessing its own budget. 
the contribution from the Community budget will take the form of  a subsidy to be entered under 
Heading B5-306.  The amount of this subsidy is estimated on the basis of  the costs referred to 
above and the fees expected to accrue from 1995 and beyond. 
The "low" hypothesis recommended by the competent Commission departments would aim to 
achieve self-sufficiency towards 1998. 
17 
)  . The "high" hypothesis would allow corrections to be made in the event of overestimates of the 
numbet of applications, and hence of the principal sources of revenue, and would provide flat-
rate  funding  (25%)  from .  the  Community  budget  to  cover  general  market-monitoring  tasks 
incumbent on the authority responsible for taking decisions, i.e., the Commission. 
a) "Low" budaet estimate. aimed at achievina self-sufficiency based on fees 
.• 
Under this hypothesis, preferable from  the point of view of budgetary discipline, the Heading 
BS-306 subsidy would enable self-sufficiency to be achieved in 1998: 
Thousands ECU  1995  1996  1997  1998  1999 
~·- .... 
Agency costs  .  25.880  38.792  44.379  62.638  68.821 
( 15 % Translation Center included)  (3.000)  (5.000)  (5.800)  (8.200)  (9.000) 
Fees··  12.545  22.347  28.284  - -
%cover  49%  58%  64%  100%  100% 
Subs.B 5-306  9.soo•  ••  ••  ••  •• 
• amount previewed by the Commission related' to the availability of ressources in the fin~cial 
perspectives.  A  consensus  at  the  budgetary  authority· level  should  allow  to  make  up  the 
difference between the high fee and the low fee hypothesis  ·  · 
•• Community subsidy to  be  determined  every  year taking  into  account  the  availability  of 
budgetary ressources in the frame of  fmancial perspectives  · 
Revenue trends 
This Regulation lays down the structure and exact amounts of the revenue expected from  the 
pharmaceuticals industry. 
The fees are fixed in such a way as not to exceed the total amount of  corresponding national fees 
required in order to obtain a marketing authorization in the 12 Member States. 
Nevertheless, .  these fees  are  high  and  could  not  be increased  at present without  placing  an 
excessive burden on the economic resources of  the undertakings oncemed.  Revenue trends as a 
functia>n of  fees are indicated in the foJJowiog table:  · 
1995 
Human  10.575.000 
Veterinary  1.970.000 
TOTAL  11.545.000 
·._, 
·:.· 
1996 
17.273.100 
5.073.900 
12.347.000 
18 
1997  from 
.21.907.660 
6.376.037 
28.283.697  probably 
.. ~" .  . 
.·.,, 
1998 
self-sufficient b) "High" budget estimate. maintaining Community co-financing 
Given that the total costs and the monitoring of the market would account for approximately a 
quarter of the activities,  this  proportion  would continue to  be  chargeable  to  the  Community 
budget if  the "high" hypothesis of  co-financing from the Community budget were to be adopted. 
Such a  hypothesis would also facilitate adju_stments  as a  function of the actual  amount of the 
revenue obtained in  the first few years after the new system became operational.  On the other 
hand, the level of  fees forming the basis of  this proposal for a Regulation would not be sufficient 
in  1995, 1996 and 1997 to achieve the envisaged rate of cover of  75%. 
Thousands ECU  1995  1996  1997  1998  1999 
Agency costs  25.880  3X.792  44.379  62.63X  6X.X21 
( 15% Translation Center included)  (3.000)  (5.000)  (5.800)  ( 8.200)  (9.000) 
Subs.B 5-306  9.500  **  **  **  ** 
Level of  fees to be reached  16.380  27.155  32.396  46.979  51.616 
%cover  63%  70%  73%  75%  75% 
**  Community  subsidy to  be  determined  every year  taking  into  account the  availability of 
budgetary ressources in the frame of  financial perspectives 
8. Anti-fraud measures 
Council Regulation (EEC) No 2309/93 of 22 July 1993 setting up the Agency for the Evaluation 
of Medicinal Products provides  for  specific adoption and  budgetary control  procedures.  Fach 
year the Management Board, made up of representatives of the Member States, the Commission 
and the European Parliament, shall be responsible for adopting the draft budget (Article 55). 
The budgetary control mechanisms are described in Article 57. 
9. Aspects of  cost-effectiveness analysis 
9.1 Objectives 
The provisions on the future system for the authorization of medicinal products seek to promote 
the free movement of medicinal products in  the Community, while at the same time providing 
better public health protection.  In  particular, they will permit rapid access lo the new medicinal 
products  available  on  the  single  market  and  ensure  greater  harmonization  of the  conditions 
governing the placing on the market of commercial  medicinal  products.  A  single evaluation, 
meeting the highest possible scientific standards, will be carried out by the European Agency for 
the Evaluation of Medicinal Products, working in  partnership with the Member States and the 
Commission.  -
19 Consequently, these provisions come under three major Community strategies: 
completion of  the intemal market in the pharmaceuticals sector; 
industrial policy to promote the competitiveness of  European companies; 
creation  of a  trans-European  communications  and  early  warning  network  linking  the 
competent authorities, the Agency .and the Commission. 
9.1 Justification for the action 
The pharmaceuticals market is characterized by a set of highly complex technical regulations 
designed  to  protect  public  health  and  the  interests  of social  security .  beneficiaries  and, 
sometimes, to promote the national  industry.  The  pharmaceuticals industry still  occupies  a 
position as one of  the leading producers and exporters of  pharmaceuticals worldwide.  However, 
the  European  market  remains  fragmented  by  virtue  of the  existence of national  marketing 
authorizations, resulting in the undermining of  the competitiveness of this industry vis-D-vis the 
American and Japanese industries, notably in the field of  advanced research. 
It does not appear feasible- or, for that matter, desirable- to dismantle the national structures, 
only to build iri their place a gigantic European Food and Drug Administration (FDA) along US 
lines.  It should· be  noted,  however,  that a  total  of nearly  3 000  staff are engaged  in  drug 
regulatory activities in the Twelve Member States, i.e., as many as in the US-FDA.  In order to 
avoid unnecessary duplication of work involving  12 separate evaluations, thus leading to the 
wasteful use of  resources and the creation of  possible sources of  conflict, it would be far better to 
share the work among the authorities concerned by introducing not only the guarantees that are 
essential· for public  health  but also sensible emulation  procedures  to  be  followed  by  all  the· 
competent authorities.  To this end, considerable efforts are needed to strengthen the evaluation 
capabilities and authority of the  European committees, so as to ensure that the opinions they 
deliver can form the basis for solutions that are accepted throughout the Community. 
The Community authorization system, as adopted by the Council, will reduce the time taken to 
examine the dossiers to less .than 300 days;  The activities of the national authorities will  be 
combined  into  a  single  European  system  leaving  wide  scope  for  decentralized  evaluation, 
inspection and control activities, while at the same time providing for centralized coordination 
for  a  small  number of new  medicinal  products  and  for  arbitration  in  the  event  of possible 
conflicts involving national decisions .. 
In  addition,  the workload  and  the estimated costs  resulting  from  the texts approved  by the 
Council have been the subject of  a major study carried out on behalf of  the Commission by the 
firms Deloitte, Touche Ross and Besselaar (DR1) following a call for tenders.  This study was 
carried out from  January to December 1992 in close collaboration with the competent national 
authorities and the manufacturers concerned. 
At the same time, it must be stressed that, for the pharmaceuticals industry, speed of access to 
the mass market and simplification of the authorization procedures (one evaluation instead of 
twelve) are crucial factors in ensuring competitiveness vis-ll-'Vis manufacturers in the USA and 
Japan.  Furthermore, a single European evaluation meeting high scientific standards will provide 
this industry with an important trump card as far as exports are concerned. 
20 Research  and development costs for  a new medicinal product are generally estimated at more 
than 200.million ecus.  Consequently, the amount in authorization fees,  forming the basis for the 
financing  of the  Agency,.appears perfectly  modest  and  reasonable:  200 000  ecus  for  a  new 
mooicinal product, i.e., 0.001% of  the total cost of  the research.  In addition, this Community fee· 
cancels and replaces an equivalent amount in fees which the firms are currently required to pay 
to the national authorities. 
The new system of authorization will also reduce the overall workload of the Member States 
which in future will be required, through the Agency, to share out the evaluation tasks hitherto 
repeated  twelve  times.  At present,  the  cumulative  operating  budget  of the  12  competent 
authorities  already exceeds the  250 million  ecu  figure  (with  the  clear likelihood  of further 
increases) as against the cost of  the Agency (27 million in  1995, 52 million in 1999), 
Looking ahead to 1999, the introduction- of the new system wiJI  be accompanied, according to 
the DRT report, by a reduction of  at least 4()GA. in the overall volume of  business. 
The cost-benefit ratio of the European  Agency as compared with  the continuation of twelve 
national evaluation systems operating along repetitive and  independent lines has already been 
demonstrated.  This multiplier effect will bring benefits not only to the relevant national budgets 
but also to the European pharmaceuticals firms themselves. 
The creation of  a European Agency with a budget of its own, funded to a large extent by fees 
from the industry for services rendered, clearly opens up the possibility of  mobilizing alternative 
sources of  funding. 
In  the  event of the Agency  not  being set  up,  the Commission  would  have to assume direct. 
responsibility for the management of  numerous meetings of  experts on the Community budget in 
order to ensure the necessary degree of scientific cooperation required by the single market in 
pharmaceuticals.  · 
9.3 Monitoring and assess'!lent of  the action 
Selected performance indicators: . 
The parameters  for judging the  efficiency of the  future  system  of authorization  and  of the 
Agency itself fall under two main categories: 
a)  Actual  number  of applications  submitted  by  the  companies  under  the  centralized  or 
decentralized  procedure, taking account of the choices  left open  to  the  undertakings and  the 
largely optional character of  the decentralized system up to 1998.  · 
21 The DRT's forecasts for applications, revised downwards by the Commission, are as follows: 
1995  1996  1997  1998  1999 
Centralized applications 
(no change) 
Human  30  32  34  36  38 
... 
Veterinary  s  10  16  14  12 
Decentralized arbitration  . 
Human  60  100  100  500  480 
Veterinary  20  54  64  144  120 
Establishment of  limits 
for veterinary residues  10  10  20  IS  IS 
b) Compliance with the 300-day evaluation and decision-making deadline, as laid down by the 
Agency and the Commission.  The speed of the new system, compared with certain  national 
deadlines (4-6 years in Germany), is a cruCial factor for the European industry. 
Evaluation procedures and frequency: 
The Regulation  provides for the adoption by the  Agency's  Management Board of an  annual 
report on the activities of  the Agency to be forwarded to the Member States, the Commission, 
the Council and the European Parliament (Article 56).  In  particular, the Executive Director of 
the Agency will be responsible for reporting on compliance with the evaluation deadlines and on 
the number ~f  different applications examined by the Agency (Article 55). 
Within six years of the entry into force of the Regulation, the Commission shall publish a full 
general report on the experience acquired under the new system, indicating, where appropriate, 
any corrective measures that need to be introduced (Article 71). 
22 IMPACT ASSESSMENT FORM 
THE IMPACT OF THE PROPOSAL OF BUSINESS 
with special reference to smatt and medium sized enterprises (SMEs) 
Title of  proposal : Proposal for a Coundl Regulation on fees payable to the EMEA 
i  ,, 
The proposal : 
1.  In order to promote the free  circulation of medicinal· products throughout the Community, 
while reinforcing the protection of public health,  the Council adopted on  14  June  1993  three 
Directives 93/39/EEC, 93/40/EEC and 93/41/EEC and  on  22  July  1993  Regulation  (EEC) n° 
2309/93, hereinafter referred to as the Basic Regulation.  (OJ n° L214 of24.08.93). 
The Basic Regulation  provides for a  new centralised Community authorisation procedure for 
technologically  advanced  medicinal  products  leading  to  a  single  Community  marketing 
authorisation valid in all Member States ..  furthermore, it sets up the European Agency for the 
Evaluation  of Medicinal  Products  to  which  applications  both  under  the  centralised  and 
decentralised procedures will have to be submitted. 
The Basic Regulation came into force·on 30.10.93, the day following the decision of the Heads 
of  States and Governments to choose London as the Headquarters of  the EMEA. 
The present proposal is an implementing Council Regulation pursuant to Art. 57 (1) and 58 
of  Council Regulation (EEC) n° 2309/93 which read as follows : 
•' 
Art. 57 (1): "The-revenues of  the Agency shatt consist ofal-;contribution from the Community, 
and  the  fees  paid  by undertakings  for  obtaining and  maintaining  a  Community  marketing 
authorisation and for other services provided by the Agency." 
,, 
Art.  58 :  "The structure and  the  amount of the  fees  referred  to  in  Article  57 (1)  shall  be 
established by the Council acting under the conditions provided for by the Treaty on a proposal 
from the Commission, following consultation of organizations representing the .interests of the 
pharmaceutical industry at Community level." 
The impact on business . 
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2.  Who will be affected by the proposal ? 
About  2000  operators  of· the  European  phannaceutical  industry  applying  for  marketing 
authorizations are concerned by the existing and the oncoming registration procedures. 
The busine~~:;~tor  concerned by the centralised procedure, and by way of  consequence, the full 
impactofthc fees Regulation is marked by large multinational companies. 
The costs of  developing new medicinal products are very high (for a major innovatory product 
up to 200 million ECU).  Therefore, companies seek to attain the "critical mass" necessary to 
finance research and development by way of  concentration.  · 
Smaller or medium sized companies in this business sector manufacture primarily conventional 
medicinal  products  whose  patent  haS  expired.  They  are  mostly  geared  to  decentralised 
procedures linked to national and even regional markets and would therefore prefer to obtain 
national marketing authorisations which would largely fall  under national fee schemes, except 
for the costs of  arbitration, in case of  conflict. 
Finally, there are a limited number of  small, highly innovatory companies concentrating on basic 
research into new therapies. 
3.  What will bUsiness have to do to comply with the proposal ? 
From  1995  onwards, the EMEA  will  play an  active role  in  two  out of three then  available 
registration procedures by fonnulating opinions of  the highest possible scientific level about the 
•  quality, safety and efficacy of  a medicinal pr9<fuct for human and veterinary use. 
Under the centralised procedure, which concerns innovatory medicinal products, the opinion of 
the  Agency  will  lead  to a final  decision  on  the  application  for  a  Community  marketing 
authorization.  The decision wilt be taken by either the Commission within the framework of a 
regulatory committee procedure o.r the Council. 
The decentralised procedure which wilt apply to the substantial majority of  medicinal products is 
based upon the principle of  mutual recognition by a variable.number of Member States of  each 
others existing marketing authorisations.  In the event of  disagreements between Member States, 
· a binding arbitration procedure at the level of  the Agency will apply from  1998 onwards (on an 
· optiot*l basis from 1.1.95). 
National  registration  procedures  limited  to applications of local  interest concerning a  single 
Member State remain possible. 
Pharmaceutical companies making use of  the new registration procedures will have to  pay fees . 
to the Agency for the work done by it just a5 they pay fees to Member States' authorities in order 
24 to obtain national marketing authorisations.  It has to be noted  that the choice of the suitable 
procedure, save the marketing of  medicinal products derived from  biotechnology, rests with the 
applicant. 
4. Economic effects of  the measure 
Fees levied by Member States' authorities for 12  different marketing authorisation  for a new 
medicinal product currently total nearly 210,000 ECU for human medicines.  This concerns only 
the first application and does not cover different strengths etc.  ,  · 
Under  the  terms  of this  proposal,  a  pharmaceutical  company  applying  for  a  Community 
marketing authorisation in the centralised procedure would have to pay a standard fee of200,000 
ECU.  This fee would be defined as a comprehensive fee covering at the choice of  the applicant 
a  bundle  of applications  for different  strengths,  schedules  of dosage,  routes  and  forms  of 
administration, and, as regards veterinary medicinal  products, the establishment of Maximum 
Residue  Limits.  Tbis is  meant to be a  major incentive for streamlined procedures and 
better cost-efficiency. It meets tbe requirement put forward by industry of baving "good 
value for money". 
As the overall cost of  resear~h and development of a new medicinal pro<!uct in  general exceeds 
200  millions  ECU,  the comprehensive cost  for  industry  to obtain  a  Community marketing 
authorization represents but one per thousand of  the overall research cost. 
Compared to the cost. the benefit derived from the new centralised procedure is significant. 
0  It is one single procedure th~oughout  the Community instead of 12 national procedures. 
0  It is a far less time consuming procedure compared to the national procedures lasting quite 
often for four or five years. 
0  It leads to a single marketing authorisation immediately valid in all Member States. 
0  It is more value for less money. 
As regards the decentralised procedure, an arbitration fee of  40,000 ECll would be levied &y the 
Agency for its services in connection with the settlement of disputes between Member States 
about the mutual recognition of  each others marketing authorizations. 
Here  too,  the  benefit  derived  from  a  system  of mutually  recognised  national  marketing 
authorisations after a  binding Community arbitration procedure clearly outweighs the cost in 
form of  the above mentioned arbitration fee. 
In  more general terms, the creation of the EMEA and its  leading role  in  the future  system's 
centralised and decentralised registration  procedure will  facilitate  the access of all  medicinal 
medicinal  products to a  Community scale  market.  This  will  lead  to  a  substantial  gain  in 
25 1 
competitiveness for  both  large  scale multinational  companies and small and medium sized 
entrepfises.  The latter quite often  lack  the resources  to  estab1ish  local  subsidiaries  in  the 
dif_ferent Member States to deal directly with national regulatory authorities.  · 
The aeeess, especially  for small and  medium sized  businesses, to  the single  European 
market will be further enhaneed by the transparency of the future system's registration 
proeeclures. 
Finally, the EMEA will foster the pre-and post-marketing co-operation between Member States 
to ensure the quality, safety and efficacy of all medicinal  products circulating in  the  Single 
European Market and will help to achieve greater international hannonisation.  · 
5. Measures to take account of  the specific situation of  small and medium sized  firms. 
A special derogatory clause is provided for under Art. 6 of the proposal to take due account of 
specific situations which might arrise for SMEs.  The case of  the abOve mentioned small sized 
but highly innovatory companies concentrating on basic research into new therapies can be seen 
in this context. 
6. Consultations 
Extensive consultation has preceeded the adoption of  the Basic Regulation as well as the current . 
proposal on fees payable to the Agency. 
A working paper on the financial arragements for the Agency has been circulated early 1993 to 
industry and other interested parties with the invitation to  submit comments by 1.5.93.  The 
dialogue with  industry continued  in  the following  months  leading to a  final  consultation  of 
organizations representing the interests of the pharmaceutical industry at Community level  in 
December 1993.  · 
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